Stockscreener 앱 받기
2.61
0.38%
0.010
시간 외 거래:
2.58
-0.03
-1.15%
전일 마감가:
$2.60
열려 있는:
$2.58
하루 거래량:
155.88K
Relative Volume:
0.10
시가총액:
$22.84M
수익:
-
순이익/손실:
-
주가수익비율:
-3.2358
EPS:
-0.8066
순현금흐름:
-
1주 성능:
-4.40%
1개월 성능:
+19.18%
6개월 성능:
-2.97%
1년 성능:
-13.00%
1일 변동 폭
$2.58
$2.675
1주일 범위
$2.57
$2.8399
52주 변동 폭
$1.33
$6.20
Neuraxis Inc Stock (NRXS) Company Profile
명칭
Neuraxis Inc
전화
(812) 689-0791
주소
11550 North Meridian Street, Suite 325, Carmel
NRXS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
2.61 | 27.25M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.232 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.34 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Neuraxis Inc 주식(NRXS)의 최신 뉴스
NeurAxis, Inc. Approves Key Proposals at Annual Meeting - TipRanks
NeurAxis, Inc. Releases Investor Presentation - TipRanks
NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 - The Manila Times
Biotech Alert: Searches spiking for these stocks today - TipRanks
NeurAxis Closes $5 Million Direct Offering - marketscreener.com
NeurAxis, Inc. Completes $5 Million Registered Direct Offering to Support Growth of IB-Stim Therapy - Nasdaq
NeurAxis Announces Closing of $5.0 Million Registered Direct Offering - GlobeNewswire
NeurAxis announces USD 5M registered direct offering - Medical Buyer
NeurAxis, Inc. Announces $5 Million Stock Offering - TipRanks
Form 424B5 Neuraxis, INC - StreetInsider
SEC Form 424B5 filed by Neuraxis Inc. - Quantisnow
NeurAxis slides 21%, raises $5M via stock - MSN
Neuraxis settles lawsuit with $750,000 agreement By Investing.com - Investing.com South Africa
NeurAxis, Inc. Receives $1 Million from Warrant Exercises - TipRanks
Neuraxis settles lawsuit with $750,000 agreement - Investing.com
Edible Garden's Sports Nutrition Launch On Amazon Sends Stocks Climbing - Finimize
NeurAxis To Sell About 1.5 Mln Stock At $3.25/shr; Stock Plunges In Pre-market - Nasdaq
NeurAxis (NRXS) Announces $5M Direct Stock Offering - GuruFocus
NeurAxis Launches $5 Million Direct Offering - marketscreener.com
NeurAxis (NRXS) Announces Direct Stock Offering to Raise $5 Mill - GuruFocus
Neuraxis prices 1.54M shares at $3.25 in registered direct offering - TipRanks
NeurAxis Announces $5.0 Million Registered Direct Offering - The Manila Times
NeurAxis Awarded First Ever FDA Clearance for the Treatment - GlobeNewswire
NeurAxis Stock Soars on Groundbreaking FDA Clearance for Pediatric Treatment - Wall Street Pit
Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings - Benzinga
Wall Street’s Dramatic Shifts Uncover Unexpected Winners and Losers—What’s Behind Today’s Wild Market Moves? - macholevante.com
NeurAxis Shares Climb After FDA Clearance of IB-Stim for Treating Pediatric Dyspepsia - marketscreener.com
NeurAxis (NRXS) Stock Surges Following Breakthrough FDA Clearance - Stocks Telegraph
Neuraxis, Inc. Common Stock (NYSE:NRXS) Stock Quote - FinancialContent
Nasdaq Falls 100 Points; Home Depot Sales Top Views - Benzinga
NRXS stock touches 52-week high of $5.67 amid market fluctuations - Investing.com
NeurAxis, Inc. Receives First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia and Associated Nausea Symptoms - marketscreener.com
Pre-market Movers: NRXS, EYEN, TIL, HCTI, EKSO... - RTTNews
NeurAxis (NRXS) Gains FDA Clearance for Expanded Use of IB-Stim - GuruFocus
Neuraxis Awarded First Ever FDA Clearance For The Treatment Of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms - marketscreener.com
Neuraxis awarded FDA clearance for treatment of pediatric FAP, FD symptoms - TipRanks
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms - Yahoo Finance
NeurAxis Stock Gains Following Strong Q1 Earnings and FDA Milestones - MSN
NeurAxis Stock Gains Following Strong Q1 Earnings And FDA Milestones - Barchart.com
NeurAxis (NRXS) Sees Q1 Revenue Surge; Eyes Future Growth Opport - GuruFocus
NeurAxis, Inc. Reports Increased Sales Amidst Losses - TipRanks
NeurAxis Earnings Call: Growth Amid Challenges - TipRanks
Transcript : NeurAxis, Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Earnings call transcript: Neuraxis sees 39% revenue boost in Q1 2025 - Investing.com Nigeria
NeurAxis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Neuraxis reports Q1 EPS (33c) vs. (32c) last year - TipRanks
NeurAxis, Inc. Reports 39% Revenue Growth in Q1 2025 Amid Expansion of Neuromodulation Therapies - Nasdaq
NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues - GlobeNewswire
Neuraxis Inc (NRXS) 재무 분석
Neuraxis Inc (NRXS)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.00%
2.33%
자본화:
|
볼륨(24시간):